Sugi Predict

Sugi Predict / Compounds / SCHEMBL3010410

SCHEMBL3010410

SCHEMBL3010410

COC(=O)C1(C)CCC(=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BUB1 O43683 1/20 0.34
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ DDB1 Q16531 3/20 0.32
▸ CRBN Q96SW2 3/20 0.32
▸ USP2 O75604 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ NR1H2 P55055 2/20 0.31
▸ PKM P14618 1/20 0.31
▸ NCOA1 Q15788 1/20 0.31
▸ NCOA3 Q9Y6Q9 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ EPHX2 P34913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17483741 1.00 BUB1 (0.34) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL3010408 1.00 BUB1 (0.34) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL1293777 0.91 BUB1 (0.35) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL4767608 0.91 BUB1 (0.35) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL631011 0.85 BUB1 (0.35) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL1293778 0.85 BUB1 (0.35) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL311298 0.85 BUB1 (0.35) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL27785365 0.81 CHRM2 (0.32) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL3658980 0.80 BUB1 (0.38) BUB1CHRM2CHRM1CHRM3DDB1
SCHEMBL6783662 0.77 BUB1 (0.34) BUB1CHRM2CHRM1CHRM3DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202836-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2025-01-21 — — US disclosed
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER (US) 2023-10-26 — — US disclosed
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2023-07-18 — — US disclosed
EP-3536685-B1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS PFIZER (US) 2022-02-16 — — EP disclosed
US-20200377511-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2020-12-03 — — US disclosed
US-10793579-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2020-10-06 — — US disclosed
EP-3536685-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS Pfizer Inc (US) 2019-09-11 — — EP disclosed
US-20190270751-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2019-09-05 — — US disclosed
US-10329302-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2019-06-25 — — US disclosed
US-20180127432-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2018-05-10 — — US disclosed
US-9879022-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2018-01-30 — — US disclosed
EP-3126330-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS Pfizer Inc (US) 2017-02-08 — — EP disclosed
US-20160347760-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2016-12-01 — — US disclosed
WO-2015150995-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS PFIZER INC. (US) 2015-10-08 — — WO disclosed
US-8415340-B2 Triazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 — — US disclosed
EP-2175933-B1 TRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-08-22 — — EP disclosed
US-20100197654-A1 TRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-05 — — US disclosed
EP-2175933-A1 TRIAZINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2010-04-21 — — EP disclosed
WO-2009015254-A1 TRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347760-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 BUB1 2648/4885CHRM2 1571/4885CHRM1 2093/4885
US-20190270751-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 BUB1 2648/4885CHRM2 1571/4885CHRM1 2093/4885
US-20100197654-A1 TRIAZINE KINASE INHIBITORS ABL1, STK25, FLT3 BUB1 209/4885CHRM2 4852/4885CHRM1 4814/4885
US-20200377511-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 BUB1 2648/4885CHRM2 1571/4885CHRM1 2093/4885
US-10793579-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 BUB1 2648/4885CHRM2 1571/4885CHRM1 2093/4885
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds TTR, TYR, ABL1 BUB1 2448/4885CHRM2 1042/4885CHRM1 1490/4885
US-10329302-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 BUB1 2648/4885CHRM2 1571/4885CHRM1 2093/4885
US-12202836-B2 Bicyclic-fused heteroaryl or aryl compounds TTR, TYR, ABL1 BUB1 2448/4885CHRM2 1042/4885CHRM1 1490/4885
US-20180127432-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 BUB1 2648/4885CHRM2 1571/4885CHRM1 2093/4885
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 BUB1 2648/4885CHRM2 1571/4885CHRM1 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.